 Connection
Paul Bunn to Mesothelioma
This is a "connection" page, showing publications Paul Bunn has written about Mesothelioma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.481 |
|
|
|
-
Carbone M, Amos C, Attanoos RL, Boeri M, Bueno R, Bunn PA, Chirieac LR, Cooper B, Fennell D, Galateau-Salle F, Giannakou L, Goparaju CV, Hassan R, Hofman P, Kris MG, Mao W, Minaai M, Mitsudomi T, Molina TJ, Montuenga LM, Nabeshima K, Passaro A, Peters S, Rajan A, Richardson DB, Robbins H, Rolfo C, Rudin CM, Samet JM, Scherpereel A, Schrump DS, Sozzi G, Taioli E, Visonà SD, Yang H, Yoshikawa Y, Zhao A, Pass HI. Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact. J Thorac Oncol. 2026 Jan; 21(1):41-76.
Score: 0.226
-
Bunn P. New investigative regimens and cytotoxic agents in thoracic cancers: gemcitabine and pemetrexed. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):5-11.
Score: 0.204
-
Bunn PA. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). Semin Oncol. 2002 Jun; 29(3 Suppl 9):17-22.
Score: 0.044
-
Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res. 1996 Feb 15; 56(4):831-9.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|